Location: Home > Company


Hanma Investment Group Co., Ltd. (HMI Group) is committed to promoting the industrial revolution of biomass to replace minerals and becoming the world leader in hemp comprehensive application industry. As the leading company in international and domestic hemp industry, HMI Group is opposed to the legalization of all forms of recreational hemp. For years, HMI Group has made positive contribution to the vigorous development of industrial use and medical use of hemp in China and made great achievements in setting industry standards and norms. At present, HMI Group is the only legal investment company in China focusing on the whole industrial chain of industrial hemp and the direction of biopharmaceutical.

As a unicorn in the industry, HMI Group focuses on the whole industrial chain investment of industrial hemp, from breeding, planting, extraction, R&D to production and sales worldwidely, covering areas of biopharmaceutical, food, health food, beauty and cosmetics, medical devices, textiles, new materials, etc. In the meantime, HMI Group keeps deepening the industry analysis and industry layout, actively developing technical and product iterations, doing research and implementing the “patent pool” strategy, strengthening the creation and application of intellectual property rights, establishing media information platform to expand the social influence of enterprise, building a global product sales network, steadily entering the global market.
HMI Group has created an interdependence and mutually beneficial industrial value chain to realize the comprehensive utilization of hemp plants. 

In the breeding and planting areas, HMI Group has invested in Yunnan Suma Bio-tech Co., Ltd., Heilongjiang Hanzheng Huoma Investment Co., Ltd., and obtained the “industrial hemp planting license” issued by public security department. Cooperated with Hemp Institute of Chinese Academy of Agricultural Sciences, Heilongjiang Academy of Sciences, HMI Group has set up ” medical hemp and fiber hemp breeding demonstration base” in Yunnan and Heilongjiang province, actively advocating the construction of “national hemp germplasm gene pool”, collecting hemp plants and wild relatives germplasm resources, and laying the foundation for cultivating hemp in line with China’s industry management policies and industrial standards and promoting their applications. Presently, the hemp variety “Huoma No.1”for fiber use has achieved crop variety registration certificate of Heilongjiang province, with more than 100 thousand mu (16474 acres) planting area. The medical hemp (high CBD) variety “Hanma No.1” has already entered the propagation stage.

In the area of medical hemp extraction, Yunnan Hansu Bio-technology Co. Ltd., (Hansu) subsidiary company of HMI Group, has built in Kunming the first industrial hemp plant extraction factory in China, approved by Yunnan provincial government and Public Security Bureau, with industrial hemp flower and leaf processing license issued. The factory was built conforming to the standard of GMP and it applies alcohol soluble fluid crystallization technology to isolate the non-psychoactive ingredient cannabidiol (CBD) from industrial hemp flowers and leaves, which has a positive and profound influence to health care industry. The factory is the world’s largest monomer CBD and cannabinoids extraction plant which can extract and separate active ingredients without psychoactive substances, as well as the only factory in the world that can industrialised the extraction of flavonoid A from hemp. As the demonstration project of Yunnan Drug Control Bureau, Hansu has achieved success in extracting pharmaceutical raw materials from hemp that has never been tried by predecessors in China before.  

The hemp industry fund, managed by Tsinghua Tusstar, and led by the Ministry of Science and Technology, Central enterprises, SOEs, will take part in the construction of phase two project of Hansu Bio-technology industrial hemp extraction base, namely Yunnan Hanmeng Pharmaceutical Co., LTD. The total investment of phase two project is nearly 350 million yuan, with 35% shares owned by Hansu through technology investment. Kings Royal Biotech Inc. (hereinafter referred to as “KRB”) invested 40 million dollars in the industrial hemp extraction plant in Kentucky. With full inspection of global hemp extraction technology, the extraction technology of Hansu is accepted by KRB and invites Hansu to have 35% technology share of KRB. The extraction plant of HMI Group invested in Nevada has been granted the breeding, planting and extraction license by the U.S. government. The plant in Las Vegas has been completed and is expected to be put into operation in the first half of 2019. The layout in China and the United States have internationalized Hansu’s preparation technology of biopharmaceuticals. Next, HMI Group will participate in the investment of Canadian medical hemp industry at the invitation of the Canadian government, thus opening the prelude of the global industrial layout.

Hansu keeps expanding domestic and international markets. The establishment of its extraction and isolation base has provided a reliable raw material and technology guarantee for exploring and studying refractory diseases such as cancer, Parkinson, Alzheimer’s disease, depression and epilepsy, and laid foundation for future biopharmaceuticals development. At present, Chinese A shares listed company Galaxy Biomed (Stock Code: 000806), Hong Kong stock listed company Meilleure Health International Group (Stock Code: HK02327) have been invested in Hansu with 5.55% and 20% shares respectively.

With a core seed variety and full licences of industrial hemp, HMI Group has set up Hanyi Bio-technology Co., Ltd., (hereinafter referred to as Hanyi Bio-technology ) in order to serve the national health strategy actively. Hanyi Bio-technology is a biopharmaceutical enterprise which is mainly engaged in drug research, drug development and commercial operation based on cannabinoids. Hanyi Bio-technology is identified by national authorities as Beijing high-tech enterprise and patent pilot unit. It is also the only company in the industry as Civil-military integrated platform for basic research and application of new drug development.

Hanyi Bio-technology invested in the construction of Life Science Research Institute and established academician workstation in cooperation with Yang Baofeng, president of Harbin Medical University. Meantime, cooperated with domestic and international well-known experts and professors, Hanyi Bio-technology has also set up the pharmaceutical research platform, pharmacological research platform, preparations development platform, plant separation technology research platform. As a major subject of “Ten Diseases and Ten Drugs” of the Beijing Science and Technology Commission, the institute has successfully declared in 2016 the “Hemp Polyphenol Tablets”, a five-class new drug of anti-epilepsy traditional Chinese medicine and obtained the approval and financial support of the Beijing Science and Technology Commission, which symbolized the support attitude of the national scientific and technological authorities to hemp pharmaceuticals. Preliminary progress has also been made in the research and development of new drugs for cancer pain alleviation in Hanyi Bio-technology, which opens a new door for hemp non-addictive drugs to replace morphine and other opioids.

Hanyi Bio-technology pays attention to the protection of intellectual property rights. It has made a comprehensive plan and layout for the global intellectual property rights of the industrial hemp industry, and has declared over eighty domestic and international patents in the field of biopharmaceutics and health. Based on solid basic research and abundant technology reserve, Hanyi Bio-technology found that CBD is effective in treating pulmonary hypertension through pharmacodynamic screening of cannabinoid. The discovery of CBD inhibiting replication of influenza A-virus shocked the world medical community. Hanyi Bio-technology has applied for international intellectual property protection. As for the worldwide problem of low bioavailability of cannabinoids, Hanyi Bio-technology has set it up as a long-term key research project and made significant breakthroughs in 2017 and developed CBD nano water-soluble technology with independent intellectual property rights, paving the way for the development of the painless and anti infectious dressings developed in cooperation with the PLA, and setting the way of cooperation with international pharmaceutical enterprises. Hanyi Bio-technology is already in the leading position of cannabinoid drug research and will surely release greater potential in the development of new drugs in the future.

In order to ensure the steady development of the pharmaceutical industry, according to the “Catalogue of Raw Materials Used for Cosmetics” by the State Administration of Food and Drug and the approval of the Drug Control Bureau of the Yunnan Provincial Public Security Bureau “the approval of the R & D and production and sales of the terminal products of cannabidiol “( This approval clearly allowed Hansu to use CBD as raw material for terminal product development, production and marketing, and clarified the legal status of CBD as “non-drug component, not included in drug control”), Hanyi Bio-technology sets up R&D platform for cosmetics and health care products, and signed a joint venture agreement with the Canadian BlueSky company to develop and sell pet health products, snacks, hair care and other products. Hanyi Bio-technology strives to quickly transform non pharmaceutical technology achievements into food, health products, cosmetics, etc., which provides strong cash flow support for continuous investment in R&D, technology iterations and other scientific research areas. HMI Group currently has established cooperations or joint venture companies with listed companies and industry leaders, including Tongrentang Group, Jinmailang Group, Nanjing Joymain, Gehua Group, Zeus Entertainment, Xinlong Holdings, Huasheng Group and so on. The downstream industry of HMI Group has entered the stage of value release.

HMI Group responds positively to the national policy “One Belt One Road” and sets the “global strategy” accordingly. As the vanguard to promote the development of civil military integration, HMI Group will continue to explore the field of bio-pharmaceutical and life sciences, inject new vitality into the development of national mass health industry and achieve the globalization of Chinese enterprises.

company structure


Promote the industrial revolution of biomass to replace minerals.


To become the world leader in the hemp industry.


A hemp industry, a lifetime career!


Chairman Mr. Zhang Ke and President Mr. Tan Xin discussed with authority to develop comprehensive utilization technology of hemp and its industrialization.


05 /

The technology innovation strategic alliance of national high value special biological resources industry was established in Beijing.


04.27 /

Strategic cooperation agreement with Heilongjiang Academy of Sciences.


05.08 /

Certificate of registration of crop varieties in Heilongjiang Province.


07.03 /

MWA Group was established, focusing on "industrial hemp, cultural media, Internet technology", the three major strategic investment area layout.


07.07 /

Cooperation agreement in hemp industry was reached with The Central Military Commission Logistics Department Quartermaster Equipment Institute of scientific research.


07.23-07.26 /

The technology innovation strategic alliance of national high value special biological resources industry council, i.e. Hemp Industry Seminar.


09.15 /

Participate in the "national high value special biological, i.e. hemp harvest ceremony.


12.21 /

The Academician Mr. Yang baofeng visited Group to discuss matters of transformation of scientific and technological products.


01.20 /

Obtain the patent right of "a kind of hemp antibacterial liquid and its preparation method and application".


04.09 /

The 2016 Global launch event of the first relaxing drink SUTIWA.


06.02 /

SUTIWA was designated as the official drink in the 2016 Asia Pacific Economic Cooperation High Level Forum.


06.15 /

The Group was invited to participate in China International New Material Industry Expo and the 27th Harbin International Economic and Trade Fair.


08.11 /

The strategic cooperation agreement was signed between the Group and Harbin Medical University.


09.09 /

Water Foundation of the Group has been identified as charitable organizations.


10.10 /

The Group was invited to attend the 1st Chinese Agricultural (Boao) Forum


11.09 /

The Group and China National Research Institute of Food & Fermentation Industries reached a strategic alliance officially.


11.14 /

The Group delegation visited industrial hemp distributor in USA.


11.15 /

Hansu Bio-technology, subsidiary of HMI Group, has built the first industrial hemp plant extraction factory in China conforming to GMP standard.


11.25 /

The Academician Workstation cooperated with Mr. Yang Baofeng, the Academician and president of Harbin Medical University, was established in Kunming city.


11.25 /

The technical innovation strategic alliance of industrial hemp industry was established in Kunming, Yunnan province.


11.25 /

The opening ceremony of Yunnan Hansu industrial hemp extraction factory--the first industrial hemp extraction factory in China.


01.15 /

Organized the Association of Sino-Russian Medical Universities Council Meeting and Academic Conference in Beijing.


03.15 /

HMI Group, Harbin Medical University and Xin long Group, visited Heihe city and planned to establish a million acres of hemp planting base.


03.20 /

HMI Group and Jiatai shoes Company signed agreement to establish a new material technology company.


03.20 /

CN PEOPLE made an exclusive report about Mr. Tan Xin, the president of HMI Group.